Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | VCP | P55072 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 2/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22520618 | 0.87 | NPC1 (0.56) | HRH3NPC1VCP | |
| SCHEMBL26949131 | 0.84 | NPC1 (0.53) | HRH3NPC1VCP | |
| SCHEMBL13086520 | 0.83 | NPC1 (0.52) | HRH3NPC1LIPGMCHR1EPHX2 | |
| SCHEMBL26949128 | 0.83 | NPC1 (0.47) | HRH3NPC1VCPCARM1 | |
| SCHEMBL18389833 | 0.82 | NPC1 (0.58) | HRH3NPC1VCP | |
| SCHEMBL24233184 | 0.81 | NPC1 (0.46) | HRH3NPC1VCPCARM1 | |
| SCHEMBL14652222 | 0.81 | NPC1 (0.46) | HRH3NPC1LIPGMCHR1MEN1 | |
| SCHEMBL25122525 | 0.80 | NPC1 (0.45) | HRH3NPC1VCPCARM1 | |
| SCHEMBL24943534 | 0.80 | HRH3 (0.44) | HRH3MEN1KMT2A | |
| SCHEMBL18855748 | 0.80 | NPC1 (0.71) | NPC1LIPGMCHR1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | JAK1, JAK2, JAK3 | HRH3 1828/4885NPC1 4245/4885VCP 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.